876345-13-0

Basic information

• Product Name: Boc-NH-PEG(3)-COOH
• Synonyms: Boc-NH-PEG(3)-COOH;Boc-NH-PEG(3)-COOH(16atoMs);Boc-NH-(PEG)4-CH2COOH;t-Boc-N-amido-PEG4-CH2CO2H;2,2-Dimethyl-4-oxo-3,8,11,14,17-pentaoxa-5-azanonadecan-19-oic acid
• CAS NO: 876345-13-0
• Molecular Formula: C14H27NO7
• Molecular Weight: 321.36668
• Mol File: 876345-13-0.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 493.6±40.0 °C(Predicted)
• Appearance: /
• Density: 1.138±0.06 g/cm3(Predicted)
• Storage Temp.: -20°C
• PKA: 3.39±0.10(Predicted)
• CAS DataBase Reference: Boc-NH-PEG(3)-COOH(CAS DataBase Reference)
• NIST Chemistry Reference: Boc-NH-PEG(3)-COOH(876345-13-0)
• EPA Substance Registry System: Boc-NH-PEG(3)-COOH(876345-13-0)

Safety Data

• Hazardous Substances Data: 876345-13-0(Hazardous Substances Data)

Usage

Description

Boc-NH-PEG(3)-COOH, also known as t-Boc-N-amido-PEG4-CH2CO2H, is a heterobifunctional PEGylated crosslinker that features a carboxylic acid at one end and a Boc-protected amino group at the other. The hydrophilic PEG linker enhances solubility in biological applications, making it suitable for various chemical biology and medicinal chemistry applications.

Uses

Used in Bioconjugation:
Boc-NH-PEG(3)-COOH is used as a crosslinker for bioconjugation, allowing the formation of stable amide bonds between the terminal carboxylic acid and primary amine groups of biomolecules in the presence of activators such as EDC or HATU.
Used in Chemical Biology and Medicinal Chemistry:
Boc-NH-PEG(3)-COOH is used as a building block for the synthesis of small molecules, conjugates of small molecules and/or biomolecules, or other tool compounds in chemical biology and medicinal chemistry that require ligation.
Used in Targeted Protein Degradation:
Boc-NH-PEG(3)-COOH is used as a component in the synthetic incorporation into antibody-drug conjugates or proteolysis-targeting chimeras (PROTAC) molecules for targeted protein degradation.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, Boc-NH-PEG(3)-COOH is used as a key intermediate for the development of drug delivery systems, improving the solubility and bioavailability of therapeutic agents.
Used in Research Applications:
Boc-NH-PEG(3)-COOH is used as a research tool for the investigation of protein-protein interactions, enzyme activity modulation, and the development of novel therapeutic agents targeting specific biological pathways.

Upstream product

• 876345-12-9 ethyl 2-[2-[2-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]ethoxy]ethoxy]acetate 
• 256397-65-6 ethyl 2-[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethoxy]acetate 
• 112-60-7 Tetraethylene glycol 
• 77544-60-6 p-toluenesulfonic acid 2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethyl ester 
• 86770-67-4 2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethanol 
• 305-53-3 monosodium iodoacetate 
• 106984-09-2 2-<2-<2-<2-<(tert-Butoxycarbonyl)amino>ethoxy>ethoxy>ethoxy>ethanol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 86770-74-3 11-amino-3,6,9-trioxaundecanol 
• 79-08-3 bromoacetic acid 
• 154773-34-9 ethyl 2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]acetate 

Downstream Products

• 2064292-52-8 (2S,4R)-1-[(2S)-2-(14-amino-3,6,9,12-tetraoxatetradecanamido)-3,3-dimethylbutanoyl]-4-hydroxy-N-[ [4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide 

Relevant articles and documents

A biocompatible condensation reaction for the labeling of terminal cysteine residues on proteins

Going live: A protein-labeling method based on the use of a single amino acid taglan N-terminal cysteine residuel and small-molecule probes containing a cyanobenzothiazole (CBT) unit has been used for the specific fluorescence labeling of proteins in vitro and at the surface of live cells (see scheme). This simople ligation reaction proceeds with a high degree of specificity under physiological conditions. Rd: a rhodamine dye; TEV: Tobacco etch virus.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

Zinc(II)cyclen-peptide conjugates interacting with the weak effector binding state of Ras

Zinc(II)cyclen-peptide hybrid compounds and bis-zinc(II)cyclen complexes are prepared as potential binders of the guanine nucleotide binding protein Ras, an important molecular switch in cellular signal transduction. The design of the compounds is based on the previous observation that zinc(II)cyclen complexes could serve as lead compounds for inhibitors of Ras-effector interaction and thus be able to interrupt Ras induced signal transduction. Zinc(II)cyclen selectively stabilizes conformational state 1 of active Ras, a conformational state with drastically decreased affinity to effector proteins like Raf-kinase. To achieve higher binding affinities of such Ras-Raf interaction inhibitors, zinc(II)cyclen conjugates with short peptides, derived from the sequence of the Ras-activator SOS, were prepared by solid phase synthesis protocols. Dinuclear bis-zinc(II)cyclen complexes were obtained from alkyne-azide cycloaddition reactions. NMR investigations of the prepared compounds revealed that the peptide conjugates do not lead to an increase in Ras binding affinity of the metal complex-peptide conjugates. The dinuclear zinc complexes lead to an immediate precipitation of the protein prohibiting spectroscopic investigations of their binding.